Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.39 |
| ▸ | ANPEP | P15144 | 5/20 | 0.38 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.38 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | LAP3 | P28838 | 2/20 | 0.34 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.34 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16857163 | 1.00 | SLC7A5 (0.50) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| SCHEMBL197500 | 1.00 | SLC7A5 (0.50) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| Hydrochloric Acid SCHEMBL2505696 | 0.98 | SLC7A5 (0.48) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| Hydrochloric Acid SCHEMBL16857161 | 0.98 | SLC7A5 (0.48) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| SCHEMBL13144609 | 0.89 | SLC7A5 (0.56) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| SCHEMBL31672557 | 0.89 | SLC7A5 (0.44) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| SCHEMBL2505997 | 0.88 | ALDH1A1 (0.47) | SLC7A5SLC1A3SLC1A2HCAR2ALDH1A1 | |
| SCHEMBL8435788 | 0.88 | ALDH1A1 (0.47) | SLC7A5SLC1A3SLC1A2HCAR2ALDH1A1 | |
| SCHEMBL8964483 | 0.88 | ALDH1A1 (0.47) | SLC7A5SLC1A3SLC1A2HCAR2ALDH1A1 | |
| SCHEMBL20509278 | 0.86 | NAAA (0.46) | SLC7A5SLC1A2HCAR2ALDH1A1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102070670-A | Purine derivatives for treating hepatitis B and preparation method and application thereof | UNIV GUIYANG MEDICAL | 2011-05-25 | — | — | CN | claimed |
| US-20250296912-A1 | AFFINITY ILLUDOFULVENE CONJUGATES | Illudent, Inc. (US) | 2025-09-25 | — | — | US | disclosed |
| US-20250241872-A1 | AFFINITY MEDICANT CONJUGATE | Illudent, Inc. (US) | 2025-07-31 | — | — | US | disclosed |
| CN-120040435-A | Mangiferin and derivatives thereof, preparation method and medical application thereof | 安徽中医药大学 | 2025-05-27 | — | — | CN | disclosed |
| US-12280021-B2 | Affinity medicant conjugate | AF CHEMICALS, LLC (US) | 2025-04-22 | — | — | US | disclosed |
| US-12269793-B2 | Affinity illudofulvene conjugates | AF CHEMICALS, LLC (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240358710-A1 | METHODS, COMPOSITIONS AND DEVICES FOR TREATING CANCER WITH ILLUDOFULVENES | AF CHEMICALS, LLC (US) | 2024-10-31 | — | — | US | disclosed |
| EP-4446310-A1 | METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND | Asahi Kasei Kabushiki Kaisha (JP) | 2024-10-16 | — | — | EP | disclosed |
| US-12023339-B2 | Methods, compositions and devices for treating cancer with illudofulvenes | AF CHEMICALS, LLC (US) | 2024-07-02 | — | — | US | disclosed |
| US-20230372267-A1 | AFFINITY MEDICANT CONJUGATE | Califia Pharma Inc. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20090197200-A1 | Resist top coat composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| CN-101495571-A | Thermoplastic resin composition and molded body thereof | MITSUI CHEMICALS INC (JP) | 2009-07-29 | — | — | CN | disclosed |
| US-20090186992-A1 | THERMOPLASTIC RESIN COMPOSITION AND MOLDED ARTICLE THEREOF | MITSUI CHEMICALS, INC (JP) | 2009-07-23 | — | — | US | disclosed |
| CN-101456970-A | Non-toxic fatty acid ester plasticiser mixture for polyvinyl chloride resin | BEIJING CHARNA CHEMICALS LTD (CN) | 2009-06-17 | — | — | CN | disclosed |
| EP-2050788-A1 | THERMOPLASTIC RESIN COMPOSITION AND MOLDED BODY THEREOF | Mitsui Chemicals, Inc. (JP) | 2009-04-22 | — | — | EP | disclosed |
| US-5741794-A | PLATELET ACTIVATING FACTOR | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-04-21 | — | — | US | disclosed |
| EP-0620813-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AS ANTAGONISTS OF PAF AND ANGIOTENSIN II | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1994-10-26 | — | — | EP | disclosed |
| WO-1993014069-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AS ANTAGONISTS OF PAF AND ANGIOTENSIN II | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1993-07-22 | — | — | WO | disclosed |
| EP-0326799-A2 | Enzymatic process for synthesizing peptides | Degussa Aktiengesellschaft (DE) | 1989-08-09 | — | — | EP | disclosed |
| US-4059589-A | Process for formylation | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DT) | 1977-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250296912-A1 | AFFINITY ILLUDOFULVENE CONJUGATES | OGFR, TNFSF11, FCER2 | SLC7A5 2532/4885SLC1A3 2053/4885SLC1A2 2878/4885 |
| US-12280021-B2 | Affinity medicant conjugate | FCER2, HDGF, FCGR2A | SLC7A5 1459/4885SLC1A3 1371/4885SLC1A2 2033/4885 |
| US-20230372267-A1 | AFFINITY MEDICANT CONJUGATE | FCER2, HDGF, FCGR2A | SLC7A5 1459/4885SLC1A3 1371/4885SLC1A2 2033/4885 |
| US-20240358710-A1 | METHODS, COMPOSITIONS AND DEVICES FOR TREATING CANCER WITH ILLUDOFULVENES | MYC, MYCBP, TP53 | SLC7A5 4844/4885SLC1A3 4586/4885SLC1A2 4601/4885 |
| US-12269793-B2 | Affinity illudofulvene conjugates | OGFR, TNFSF11, FCER2 | SLC7A5 2532/4885SLC1A3 2053/4885SLC1A2 2878/4885 |
| US-20090186992-A1 | THERMOPLASTIC RESIN COMPOSITION AND MOLDED ARTICLE THEREOF | TRIM59, TRIM4, MAP1LC3C | SLC7A5 1510/4885SLC1A3 1853/4885SLC1A2 2095/4885 |
| US-12023339-B2 | Methods, compositions and devices for treating cancer with illudofulvenes | MYC, MYCBP, TP53 | SLC7A5 4844/4885SLC1A3 4586/4885SLC1A2 4601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.